Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of CKBA ointment in mild to moderate plaque psoriasis
ChiCTR2200059721Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 3-O-cyclohexanecarbonyl-11-keto-β-boswellic acid in plaque psoriasis (6 arms), sponsored by Peking University People's Hospital. Primary endpoints: Laboratory parameters, 12-lead electrocardiogram and 5 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
3-O-cyclohexanecarbonyl-11-keto-β-boswellic acid
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2200059721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059721.